Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLUENASDAQ:CRSPNASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUEbluebird bio$4.95+1.2%$5.29$3.56▼$28.60$48.46M0.41381,819 shs218,782 shsCRSPCRISPR Therapeutics$32.650.0%$42.37$30.20▼$67.88$2.80B1.851.58 million shs3.08 million shsVRTXVertex Pharmaceuticals$474.62-1.9%$480.84$377.85▼$519.88$121.88B0.51.29 million shs2.88 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUEbluebird bio-2.78%+29.02%+28.01%-46.73%-79.28%CRSPCRISPR Therapeutics-4.47%-14.14%-24.83%-20.38%-49.44%VRTXVertex Pharmaceuticals+0.11%-3.69%-0.45%+18.89%+18.39%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUEbluebird bio2.8031 of 5 stars3.13.00.00.03.02.51.3CRSPCRISPR Therapeutics3.0375 of 5 stars4.22.00.00.02.03.30.6VRTXVertex Pharmaceuticals3.6519 of 5 stars2.33.00.03.32.92.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUEbluebird bio 2.25Hold$44.60801.01% UpsideCRSPCRISPR Therapeutics 2.48Hold$73.11123.91% UpsideVRTXVertex Pharmaceuticals 2.65Moderate Buy$509.177.28% UpsideCurrent Analyst Ratings BreakdownLatest BLUE, VRTX, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025VRTXVertex PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$408.00 ➝ $420.003/31/2025BLUEbluebird bioBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $8.003/31/2025VRTXVertex PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$555.00 ➝ $567.002/24/2025BLUEbluebird bioWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$40.00 ➝ $5.002/24/2025BLUEbluebird bioJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Neutral2/21/2025BLUEbluebird bioBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold2/20/2025VRTXVertex PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$407.00 ➝ $408.002/19/2025CRSPCRISPR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral2/18/2025CRSPCRISPR TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$89.00 ➝ $82.002/14/2025CRSPCRISPR TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderweight ➝ Underweight$30.00 ➝ $32.002/14/2025CRSPCRISPR TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeIn-Line ➝ Outperform$60.00 ➝ $99.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUEbluebird bio$83.81M0.58N/AN/A$35.59 per share0.14CRSPCRISPR Therapeutics$35M80.01N/AN/A$22.52 per share1.45VRTXVertex Pharmaceuticals$11.02B11.06N/AN/A$63.90 per share7.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUEbluebird bio-$211.91M-$45.54N/AN/AN/A-565.74%-322.46%-53.17%5/7/2025 (Estimated)CRSPCRISPR Therapeutics-$366.25M-$4.37N/AN/AN/A-981.54%-18.46%-15.79%5/6/2025 (Estimated)VRTXVertex Pharmaceuticals-$535.60M-$2.20N/A27.112.11-4.86%-2.02%-1.49%5/5/2025 (Estimated)Latest BLUE, VRTX, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/11/2025Q4 2024CRSPCRISPR Therapeutics-$1.15-$0.44+$0.71-$0.44N/AN/A2/10/2025Q4 2024VRTXVertex Pharmaceuticals$3.99$3.54-$0.45$3.50$2.78 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUEbluebird bioN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUEbluebird bio0.370.510.33CRSPCRISPR TherapeuticsN/A22.0722.07VRTXVertex Pharmaceuticals0.012.692.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUEbluebird bio87.43%CRSPCRISPR Therapeutics69.20%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipBLUEbluebird bio1.40%CRSPCRISPR Therapeutics4.10%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableCRSPCRISPR Therapeutics47385.77 million82.26 millionOptionableVRTXVertex Pharmaceuticals6,100256.79 million256.28 millionOptionableBLUE, VRTX, and CRSP HeadlinesRecent News About These CompaniesBryce Point Capital LLC Makes New $1.74 Million Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 4 at 6:59 AM | marketbeat.comKesler Norman & Wride LLC Reduces Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 4 at 5:38 AM | marketbeat.comCorporate CFOs Think a Recession Is Coming. Here Are 3 Stocks to Own If They're Right.April 4 at 4:42 AM | fool.comEdmond DE Rothschild Holding S.A. Cuts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 4 at 4:41 AM | marketbeat.comVertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to KnowApril 3 at 6:55 PM | zacks.comWells Fargo Remains a Hold on Vertex Pharmaceuticals (VRTX)April 3 at 5:27 PM | markets.businessinsider.comVertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $420.00April 3 at 12:24 PM | marketbeat.comTe Ahumairangi Investment Management Ltd Has $5 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 3 at 6:35 AM | marketbeat.comMassachusetts Financial Services Co. MA Sells 617,207 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 3 at 6:34 AM | marketbeat.comPetri Dish: Vertex halts type 1 diabetes trial; Watertown manufacturer soldApril 3 at 6:13 AM | bizjournals.comMay Hill Capital LLC Acquires New Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 3 at 6:07 AM | marketbeat.comNational Bank of Canada FI Sells 75,698 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 3 at 5:36 AM | marketbeat.comFranklin Resources Inc. Raises Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 3 at 5:27 AM | marketbeat.comRoyal Bank of Canada Increases Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $420.00April 3 at 1:49 AM | americanbankingnews.comIs Vertex Pharmaceuticals Incorporated (VRTX) the Best Gene-Editing Stock to Buy?April 3 at 12:18 AM | finance.yahoo.comGroupama Asset Managment Raises Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 2 at 7:07 AM | marketbeat.comTweedy Browne Co LLC Sells 12,969 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 2 at 6:54 AM | marketbeat.comGeode Capital Management LLC Sells 287,652 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 2 at 6:27 AM | marketbeat.comSchroder Investment Management Group Has $65.35 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)April 2 at 4:49 AM | marketbeat.comTrump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocksApril 1 at 2:01 PM | cnbc.comVRTX Provides Mixed Updates for Type 1 Diabetes Pipeline CandidatesApril 1 at 11:55 AM | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBLUE, VRTX, and CRSP Company Descriptionsbluebird bio NASDAQ:BLUE$4.95 +0.06 (+1.23%) Closing price 04:00 PM EasternExtended Trading$4.85 -0.10 (-2.02%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.CRISPR Therapeutics NASDAQ:CRSP$32.65 -0.01 (-0.03%) Closing price 04:00 PM EasternExtended Trading$32.72 +0.07 (+0.21%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Vertex Pharmaceuticals NASDAQ:VRTX$474.62 -9.39 (-1.94%) Closing price 04:00 PM EasternExtended Trading$476.82 +2.20 (+0.46%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
